Actelion selects its molecular drug targets on the basis of the established platforms of expertise, capabilities, technologies and the professionals at its research center. Actelion’s drug hunters all have the opportunity to suggest a new target and follow the evaluation process. Additional selection criteria which the proposed projects are required to demonstrate include:
We use our expertise to address a variety of therapeutic areas including cardiovascular disorders, central nervous system disorders, infectious diseases, cancer, immunological disorders, fibrosis and neurodegeneration.
We aim to tackle diseases through multiple mechanisms, delivering novel therapies to patients, with maximum impact on the selected diseases.